Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial

<p><strong>Introduction:</strong> COVID-19 convalescent plasma (CCP) is a possible treatment option for COVID-19. A comprehensive number of clinical trials on CCP efficacy have already been conducted. However, many aspects of CCP treatment still require investigations: in...

Full description

Bibliographic Details
Main Authors:	Desmarets, M, Hoffmann, S, Vauchy, C, Rijnders, BJA, Toussirot, E, Durrbach, A, Körper, S, Schrezenmeier, E, van der Schoot, CE, Harvala, H, Brunotte, G, Appl, T, Seifried, E, Tiberghien, P, Bradshaw, D, Roberts, DJ, Estcourt, LJ, Schrezenmeier, H
Format:	Journal article
Language:	English
Published:	BMJ Publishing 2023

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial

Similar Items